Ignite Creation Date:
2024-05-06 @ 7:18 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02504229
Status:
UNKNOWN
Last Update Posted:
2015-07-21
First Post:
2015-07-20
Brief Title:
DC-CIK In Combination With Chemotherapy Gio Oxaliplatin or Cisplatin Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment
Sponsor:
Beijing Biohealthcare Biotechnology CoLtd
Organization:
Beijing Biohealthcare Biotechnology CoLtd
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2015-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the therapeutic effects of autologous dendritic cells co-cultured with cytokine-induced killer cells DC-CIK combined with S-1 Tegafur Gimeracil and Oteracil Potassium and oxaliplatin adjuvant chemotherapy in locally advanced unresectable or metastaticgastric cancer Half of participants will receive DC-CIK combined with S-1 and oxaliplatin adjuvant chemotherapywhile the other half will receive S-1 and oxaliplatin adjuvant chemotherapy served as controls
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None